WHAT IS CLAIMED IS:

1. CER-001 for use in a method of treating kidney disease in a subject.

2. CER-001 for use according to claim 1, wherein the subject has glomerulopathy.

3. CER-001 for use according to claim 1 or claim 2, wherein the subject has an LCAT deficiency, optionally wherein the LCAT deficiency is an acquired LCAT deficiency.

4. CER-001 for use according to any one of claims 1 to 3, wherein the subject has an LCAT mutation, optionally wherein the subject is homozygous for an LCAT mutation or heterozygous for an LCAT mutation.

5. CER-001 for use according to any one of claims 1 to 4, wherein the subject has diabetic nephropathy.

6. CER-001 for use according to any one of claims 1 to 5, wherein the subject has chronic kidney disease (CKD).

7. CER-001 for use according to any one of claims 1 to 6, wherein the subject has hepatorenal syndrome (HRS) or is at risk of HRS.

8. CER-001 for use according to any one of claims 1 to 7, wherein the subject is undergoing hemodialysis.

9. CER-001 for use according to any one of claims 1 to 7, wherein the subject is a candidate for hemodialysis, optionally wherein the treatment delays the subject's need to initiate hemodialysis.

10. CER-001 for use according to any one of claims 1 to 9, wherein the subject has undergone a kidney transplant.

11. CER-001 for use according to any one of claims 1 to 9, wherein the subject has not undergone a kidney transplant.

12. CER-001 for use according to any one of claims 1 to 11, wherein the treatment delays a need for a kidney transplant in the subject.

13. CER-001 for use according to any one of claims 1 to 12, wherein in the method CER-001 is administered to the subject according to a dosing regimen which comprises:

(a) an induction regimen; and/or

(b) a consolidation regimen; and/or

(c) a maintenance regimen.

14. CER-001 for use according to claim 13, wherein the dosing regimen comprises an induction regimen comprising one or more doses of CER-001.

15. CER-001 for use according to claim 14, wherein the induction regimen comprises multiple doses of CER-001, optionally wherein:

(a) the induction regimen comprises at least three doses of CER-001; and/or

(b) the multiple doses in the induction regimen are separated by 1 or more days.

16. CER-001 for use according to claim 14 or 15, wherein the doses following the initial dose of the induction regimen are separated by no more than 3 days, optionally wherein:

(a) the doses following the initial dose of the induction regimen are separated by one to three days;

(b) the doses following the initial dose of the induction regimen are separated by two to three days; or

(c) the doses following the initial dose of the induction regimen are separated by one to two days.

17. CER-001 for use according to any one of claims 14 to 16, wherein the induction regimen is for a duration of at least one week.

18. CER-001 for use according to claim 17, wherein the induction regimen is for a duration of two weeks or three weeks.

19. CER-001 for use according to any one of claims 14 to 18, in which the induction regimen comprises administering to the subject three doses of CER-001 per week.

20. CER-001 for use according to any one of claims 14 to 19, wherein the induction regimen comprises administering to the subject:

(a) four or more doses of CER-001;

(b) five or more doses of CER-001;

(c) six or more doses of CER-001;

(d) seven or more doses of CER-001;

(e) eight or more doses of CER-001; or

(f) nine or more doses of CER-001.

21. CER-001 for use according to claim 20, wherein the induction regimen comprises nine doses of CER-001 administered over three weeks.

22. CER-001 for use according to claim 20, wherein the induction regimen comprises administering the first dose of CER-001 to the subject on day 1 and administering subsequent doses of the induction regimen to the subject on days 2, 4, 7, 9, 11, 14, 16, and 18.

23. CER-001 for use according to any one of claims 13 to 22, wherein the dosing regimen comprises a consolidation regimen, optionally wherein the consolidation regimen comprises multiple doses of CER-001.

24. CER-001 for use according to claim 23, in which multiple doses in the consolidation regimen are separated by 2 or more days.

25. CER-001 for use according to claim 23 or claim 24, wherein the consolidation regimen comprises administering at least two doses of CER-001 to the subject in one week.

26. CER-001 for use according to any one of claims 23 to 25, wherein the doses of the consolidation regimen are separated by no more than four days.

27. CER-001 for use according to any one of claims 23 to 26, wherein the doses of the consolidation regimen are separated from one another by three or four days.

28. CER-001 for use according to any one of claims 23 to 27, wherein the consolidation regimen is for a duration of at least 3 weeks.

29. CER-001 for use according to any one of claims 23 to 28, wherein the consolidation regimen comprises administering to the subject:

(a) three or more doses of CER-001;

(b) four or more doses of CER-001;

(c) five or more doses of CER-001;

(d) six or more doses of CER-001;

(e) seven or more doses of CER-001;

(f) eight or more doses of CER-001;

(g) nine or more doses of CER-001; or

(h) ten or more doses of CER-001.

30. CER-001 for use according to claim 29, wherein the consolidation regimen comprises six doses of CER-001 administered over three weeks.

31. CER-001 for use according to claim 29, wherein the consolidation regimen comprises administering six doses of CER-001 to the subject on days 21, 24, 28, 31, 35, and 38 following an induction regimen which begins on day 1.

32. CER-001 for use according to any one of claims 13 to 31, wherein the dosing regimen comprises a maintenance regimen.

33. CER-001 for use according to claim 32, wherein the maintenance regimen comprises administering a dose of CER-001 to the subject:

(a) once every 3 or more days;

(b) once every 5 or more days;

(c) weekly, optionally wherein the doses of the maintenance regimen are administered +/- 2 days around the strict weekly date; or

(d) twice weekly.

34. CER-001 for use according to claim 32 or claim 33, wherein the maintenance regimen comprises administering CER-001 to the subject:

(a) for at least one month;

(b) for at least two months;

(c) for at least three months;

(d) for at least six months;

(e) for at least nine months;

(f) for at least a year;

(g) for at least 18 months;

(h) for at least 2 years;

(i) indefinitely;

(j) for 16 or more weeks;

(k) for 20 or more weeks;

(l) for 30 or more weeks; or

(m) for 40 or more weeks.

35. CER-001 for use according to any one of claims 13 to 34, wherein the dose of CER-001 administered in the induction regimen is:

(a) 4 to 30 mg/kg (on a protein weight basis);

(b) 5 to 15 mg/kg (on a protein weight basis);

(c) 10 to 20 mg/kg (on a protein weight basis);

(d) 15 to 25 mg/kg (on a protein weight basis);

(e) 8 mg/kg (on a protein weight basis);

(f) 10 mg/kg (on a protein weight basis);

(g) 300 mg to 3000 mg;

(h) 300 mg to 1500 mg;

(i) 400 mg to 1500 mg;

(j) 500 mg to 1200 mg; or

(k) 500 mg to 1000 mg.

36. CER-001 for use according to any one of claims 13 to 35, wherein the dose of CER-001 administered in the consolidation regimen is:

(a) 4 to 30 mg/kg (on a protein weight basis);

(b) 5 to 15 mg/kg (on a protein weight basis);

(c) 10 to 20 mg/kg (on a protein weight basis);

(d) 15 to 25 mg/kg (on a protein weight basis);

(e) 8 mg/kg (on a protein weight basis);

(f) 10 mg/kg (on a protein weight basis);

(g) 300 mg to 3000 mg;

(h) 300 mg to 1500 mg;

(i) 400 mg to 1500 mg;

(j) 500 mg to 1200 mg; or

(k) 500 mg to 1000 mg.

37. CER-001 for use according to any one of claims 13 to 36, wherein the dose of CER-001 administered in the maintenance regimen is:

(a) 4 to 30 mg/kg (on a protein weight basis);

(b) 5 to 15 mg/kg (on a protein weight basis);

(c) 10 to 20 mg/kg (on a protein weight basis);

(d) 15 to 25 mg/kg (on a protein weight basis);

(e) 8 mg/kg (on a protein weight basis);

(f) 10 mg/kg (on a protein weight basis);

(g) 20 mg/kg (on a protein weight basis);

(h) 300 mg to 3000 mg;

(i) 300 mg to 1500 mg;

(j) 400 mg to 1500 mg;

(k) 500 mg to 1200 mg; or

(l) 500 mg to 1000 mg.

38. CER-001 for use according to any one of claims 13 to 37, which comprises both an induction regimen and a maintenance regimen.

39. CER-001 for use according to claim 38, wherein the dose of CER-001 administered in the induction regimen and the dose of CER-001 administered in the maintenance regimen are the same.

40. CER-001 for use according to claim 38, wherein the dose of CER-001 administered in the induction regimen and the dose of CER-001 administered in the maintenance regimen are different, optionally wherein:

(a) the dose of CER-001 administered in the maintenance regimen is greater than the dose of CER-001 administered in the induction regimen;

(b) the dose of CER-001 administered in the maintenance regimen is 1.5 to 3 times the dose of CER-001 administered in the induction regimen; or

(c) the dose of CER-001 administered in the maintenance regimen is 2 times the dose administered in the induction regimen.

41. CER-001 for use according to any one of claims 13 to 40, which comprises both a consolidation regimen and a maintenance regimen.

42. CER-001 for use according to claim 41, wherein the dose of CER-001 administered in the consolidation regimen and the dose of CER-001 administered in the maintenance regimen are the same.

43. CER-001 for use according to claim 41, wherein the dose of CER-001 administered in the consolidation regimen and the dose of CER-001 administered in the maintenance regimen are different, optionally wherein:

(a) the dose of CER-001 administered in the maintenance regimen is greater than the dose administered in the consolidation regimen;

(b) the dose of CER-001 administered in the maintenance regimen is 1.5 to 3 times the dose of CER-001 administered in the consolidation regimen; or

(c) the dose of CER-001 administered in the maintenance regimen is 2 times the dose administered in the consolidation regimen.

44. CER-001 for use according to any one of claims 1 to 43, wherein in the method an antihistamine is administered prior to administration of one or more of the CER-001 doses.

45. CER-001 for use according to any one of claims 1 to 44, wherein the subject is a subject treated with a lipid control medication, optionally wherein the lipid control medication comprises:

(a) a statin, optionally wherein the statin is atorvastatin, rosuvastatin, simvastatin, fluvastatin, lovastatin, or pravastatin;

(b) a cholesterol absorption inhibitor, optionally wherein the cholesterol absorption inhibitor is ezetimibe;

(c) niacin;

(d) aspirin;

(e) a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, optionally wherein the PCSK9 inhibitor is (i) an antibody, optionally wherein the antibody is alirocumab, bococizumabevolocumab, 1D05-IgG2 or LY3015014, or (ii) an RNAi therapeutic, optionally wherein the RNAi therapeutic is ALN-PCSSC; or

(f) a combination of (a)-(e).